CALGB 80403/E1206: Randomized Phase II Study of ECF-C, IC-C, or Folfox-C in Metastatic Esophageal and GE Junction Cancer.

Trial Profile

CALGB 80403/E1206: Randomized Phase II Study of ECF-C, IC-C, or Folfox-C in Metastatic Esophageal and GE Junction Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Epirubicin; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jul 2016 Results published in the Journal of Clinical Oncology
    • 06 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 15 Oct 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top